PARMAR KUSH

CIK 000166428117 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001664281

Recent Transactions

50 trades

Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-11-14$8.80/sh−200,000→ 2,963,066 total
Purchase
Camp4 Therapeutics Corp$CAMP
Common Stock
2025-09-11$1.53/sh+2,941,176→ 2,941,176 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-22$3.42/sh−163,979→ 1,457,064 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-22$3.42/sh−6,470→ 57,493 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-21$3.57/sh−2,314→ 63,963 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2025-08-21$3.57/sh−58,642→ 1,621,043 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-07-09$7.50/sh−6,935→ 1,093,313 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-07-09$7.50/sh−20,065→ 3,163,066 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-07-01$7.12/sh−18,578→ 3,183,131 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-07-01$7.12/sh−6,422→ 1,100,248 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-06-30$6.81/sh−18,578→ 3,201,709 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-06-30$6.81/sh−6,422→ 1,106,670 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-06-27$6.91/sh−19,265→ 1,113,092 total
Sale
Entrada Therapeutics, Inc.$TRDA
Common Stock
2025-06-27$6.91/sh−55,735→ 3,220,287 total
Award
Entrada Therapeutics, Inc.$TRDA
Stock Option (Right to Buy)
2025-06-11+19,000→ 19,000 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series B Preferred Stock
2024-10-15−4,244,770→ 0 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series B Preferred Stock
2024-10-15−3,395,816→ 0 total
Conversion
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15+302,770→ 302,770 total
Conversion
Camp4 Therapeutics Corp$CAMP
Series A Prime Preferred Stock
2024-10-15−15,002,166→ 0 total
Conversion
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15+1,716,055→ 1,716,055 total
Purchase
Camp4 Therapeutics Corp$CAMP
Common Stock
2024-10-15$11.00/sh+909,090→ 2,625,145 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−2,000→ 1,679,685 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−79→ 66,277 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-13$6.06/sh−11,758→ 8,167,206 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−214,556→ 8,178,964 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−1,440→ 66,356 total
Sale
Skye Bioscience, Inc.$SKYE
Common Stock
2024-09-11$6.60/sh−36,504→ 1,681,685 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Series A Preferred Stock
2024-07-22−843,592→ 0 total
Other
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22$10.20/sh+112,966→ 1,171,250 total
Purchase
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22$12.00/sh+833,333→ 1,182,054 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Series B Preferred Stock
2024-07-22−214,692→ 0 total
Other
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22$10.20/sh+348,721→ 348,721 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22+1,058,284→ 1,058,284 total
Award
Entrada Therapeutics, Inc.$TRDA
Stock Option (Right to Buy)
2024-06-13+16,000→ 16,000 total
Award
Rallybio Corp$RLYB
Option (Right to Buy)
2024-05-15+16,500→ 16,500 total
Purchase
Skye Bioscience, Inc.$SKYE
Common Stock
2024-03-13$10.00/sh+450,000→ 8,393,520 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2024-02-14$14.90/sh−688,358→ 3,200,634 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2024-02-14$14.90/sh−136,642→ 635,341 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2024-01-31$15.00/sh−82,813→ 771,983 total
Purchase
Skye Bioscience, Inc.$SKYE
Common Stock
2024-01-31$2.31/sh+5,206,074→ 7,943,520 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2024-01-31$15.00/sh−417,187→ 3,888,992 total
Award
Rallybio Corp$RLYB
Option (Right to Buy)
2024-01-02$1.77/sh+27,118→ 27,118 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-09-26$15.00/sh−164,789→ 4,306,179 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-09-26$15.00/sh−32,711→ 854,796 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-08-24$16.00/sh−367,124→ 4,470,968 total
Sale
Enliven Therapeutics, Inc.$ELVN
Common Stock
2023-08-24$16.00/sh−72,876→ 887,507 total
Award
Entrada Therapeutics, Inc.$TRDA
Stock Option (Right to Buy)
2023-06-08+16,000→ 16,000 total
Award
Rallybio Corp$RLYB
Option (Right to Buy)
2023-05-17+15,490→ 15,490 total
Sale
Rallybio Corp$RLYB
Common Stock
2023-03-07$8.20/sh−100,000→ 2,378,969 total
Disposition from Tender
CinCor Pharma, Inc.
Common Stock
2023-02-24−487,333→ 0 total

Companies

Recent Filings

Address

C/O 5AM VENTURE MANAGEMENT, LLC 4 EMBARCADERO CENTER, SUITE 3110

SAN FRANCISCO, CA, 94111

View on SEC.gov